Tradestie Institutional Equity Comparison Engine
CRIS vs BGMSP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRIS Overall Edge
CRIS Captures Institutional Edge (3โ0 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Curis Inc (CRIS) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, CRIS trades at N/M Forward P/E with -833.4% operating margin (-66.0% YoY revenue) versus BGMSP at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, CRIS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BGMSP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
CRIS
CRIS N/M vs BGMSP N/M Fwd P/E
Growth & Margin Winner
CRIS
Op Margin -833.4% vs N/A ยท YoY -66.0% vs N/A
Momentum & Technical Winner
CRIS
1Y -61.0% vs -72.6% ยท 52W Pos 4% vs 0%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CRIS
NASDAQ
Curis Inc
Biological Products, (No Disgnostic Substances)
$0.44
-1.07% 1D
Market Cap
$3.8M
1M Return
+8.14%
1Y Return
-61.04%
Forward P/E
N/M
Unified AI Score
38.7 / 100
SELL
Tech 15.0
Fund 41.0
Flow 50.0
Mom 64.0
BGMSP
US Equity
BGMSP
Institutional Equity
$1.44
-39.75% 1D
Market Cap
N/A
1M Return
-60.98%
1Y Return
-72.57%
Forward P/E
N/M
Unified AI Score
42.7 / 100
HOLD
Tech 45.0
Fund 48.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CRIS -61.04%
BGMSP -72.57%
Spread: +30.39 pp (CRIS Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CRIS TTM Op. Margin: -833.4%
BGMSP TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRIS vs BGMSP. Trailing 12-month operating profitability (CRIS -833.4% vs BGMSP N/A) and valuation multiples (CRIS N/M vs BGMSP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRIS | BGMSP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.8M | N/A | Larger Scale | CRIS |
| Trailing P/E Ratio Valuation | 0.4x | N/M | Lower Multiple | CRIS |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -66.0% | N/A | Higher Growth | CRIS |
| Operating Margin (TTM) Profitability | -833.4% | N/A | Higher Margin | CRIS |
| Net Profit Margin Profitability | 0.0% | N/A | Higher Margin | CRIS |
| Return on Equity (ROE) Capital Efficiency | -693.9% | N/A | Higher ROE | CRIS |
| 52-Week Range Position Momentum | 4% ($0โ$7) | 0% ($1โ$14) | Stronger Trend | CRIS |
| Beta / 30D Volatility Risk Regime | 11.40ฮฒ ยท 269% Vol | 0.59ฮฒ ยท 201% Vol | Lower Realized Risk | BGMSP |
| Unified Institutional Score Composite Signal | 38.7 / 100 (SELL) | 42.7 / 100 (HOLD) | Higher Composite | BGMSP |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CRIS vs BGMSP Buy Guide
CRIS
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
BGMSP
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CRIS nor BGMSP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.